Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CELU 
Celularity Inc (CELU)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/01/2025: CELU (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $2.5
1 Year Target Price $2.5
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -28.1% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 56.92M USD | Price to earnings Ratio - | 1Y Target Price 2.5 |
Price to earnings Ratio - | 1Y Target Price 2.5 | ||
Volume (30-day avg) 1 | Beta 0.78 | 52 Weeks Range 1.00 - 4.35 | Updated Date 12/2/2025 |
52 Weeks Range 1.00 - 4.35 | Updated Date 12/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.33 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-11-17 | When - | Estimate - | Actual -0.8758 |
Profitability
Profit Margin -198.75% | Operating Margin (TTM) -243.17% |
Management Effectiveness
Return on Assets (TTM) -25.03% | Return on Equity (TTM) -6367.24% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 123299760 | Price to Sales(TTM) 1.4 |
Enterprise Value 123299760 | Price to Sales(TTM) 1.4 | ||
Enterprise Value to Revenue 3.04 | Enterprise Value to EBITDA -36.78 | Shares Outstanding 28316485 | Shares Floating 17133307 |
Shares Outstanding 28316485 | Shares Floating 17133307 | ||
Percent Insiders 39.57 | Percent Institutions 13.45 |
Upturn AI SWOT
Celularity Inc
Company Overview
History and Background
Celularity Inc. was founded in 2016 and is a biotechnology company focused on developing and commercializing allogeneic cell therapies and biomaterial products. It was formed through a merger with a special purpose acquisition company (SPAC). Celularity leverages placental-derived cells to treat diseases across immune and degenerative areas.
Core Business Areas
- Cell Therapy Development: Focuses on developing allogeneic cell therapies derived from the placenta for various diseases, including hematological malignancies and autoimmune diseases.
- Biomaterial Products: Involves the development and commercialization of biomaterial products for regenerative medicine and wound care applications.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of its cell therapies and biomaterial products.
Leadership and Structure
Celularity's leadership team consists of experienced professionals in biotechnology and pharmaceuticals. The organizational structure is designed to support research and development, clinical trials, and commercialization efforts.
Top Products and Market Share
Key Offerings
- CYNK-001: An allogeneic natural killer (NK) cell therapy being developed for hematological malignancies and solid tumors. It is currently in clinical trials. Competitors include Fate Therapeutics and Nkarta Therapeutics, and major pharmaceutical companies with competing therapies such as Novartis and Bristol Myers Squibb. Market share data not publicly available.
- PDA-002: A placental-derived product developed for wound healing. Market share data is limited, and competitors include Integra LifeSciences and Organogenesis, and large companies in wound care such as 3M and Smith & Nephew. Revenue for the product is minimal.
Market Dynamics
Industry Overview
The cell therapy and regenerative medicine industry is rapidly growing, driven by advances in biotechnology and increasing demand for innovative therapies for various diseases.
Positioning
Celularity is positioned as a leader in placental-derived cell therapies, leveraging its proprietary technology platform to develop novel treatments.
Total Addressable Market (TAM)
The TAM for cell therapies and regenerative medicine is projected to reach billions of dollars. Celularity is positioned to capture a share of this market with its pipeline of cell therapy candidates and biomaterial products.
Upturn SWOT Analysis
Strengths
- Proprietary placental-derived cell therapy platform
- Strong intellectual property portfolio
- Experienced management team
- Potential for breakthrough therapies
Weaknesses
- Limited commercial product revenue
- High cash burn rate
- Dependence on clinical trial success
- Relatively small market capitalization
Opportunities
- Expansion into new therapeutic areas
- Partnerships with pharmaceutical companies
- Increased adoption of cell therapies
- Positive clinical trial results
Threats
- Regulatory hurdles
- Competition from other cell therapy companies
- Clinical trial failures
- Financial constraints
Competitors and Market Share
Key Competitors
- NKTA
- CRIS
- BMY
Competitive Landscape
Celularity faces competition from other cell therapy companies with more advanced products and stronger financial resources. Its placental-derived cell therapy platform provides a potential competitive advantage.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited due to the company's focus on research and development.
Future Projections: Future growth depends on the successful development and commercialization of its cell therapy candidates.
Recent Initiatives: Recent initiatives include advancing clinical trials for CYNK-001 and PDA-002, and seeking strategic partnerships.
Summary
Celularity is a biotechnology company focused on placental-derived cell therapies. While it has a novel technology platform and potential for breakthrough therapies, it faces challenges related to limited revenue, high cash burn, and clinical trial risks. The company's future success depends on the successful development and commercialization of its pipeline. Celularity must overcome current financial constraints and competition from larger, more established players.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings, investor presentations, press releases, analyst reports.
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share figures are estimates and may not be precise. Financial data may not be current. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Celularity Inc
Exchange NASDAQ | Headquaters Florham Park, NJ, United States | ||
IPO Launch date 2019-08-08 | Founder, CEO & Chairman Dr. Robert Joseph Hariri M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 123 | Website https://www.celularity.com |
Full time employees 123 | Website https://www.celularity.com | ||
Celularity Inc., a regenerative and cellular medicines company, focuses on addressing aging-related and degenerative diseases. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn's) and degenerative disease; and PDA-002 for treating facioscapulohumeral muscular dystrophy. The company is also developing pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. In addition, it produces, sells, and licenses products used in surgical and wound care markets, such as Biovance, Biovance 3L, Rebound, Interfyl, and Centaflex; and collects, processes, and stores umbilical cord and placental blood and tissue after full-term pregnancies under the LifebankUSA brand. Celularity Inc. has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. Celularity Inc. was founded in 1998 and is headquartered in Florham Park, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.